MedPath

Treatment of Recurrent Bladder Cancer With Dendritic Cells

Phase 2
Completed
Conditions
Bladder Cancer
Interventions
Biological: Dendritic cells
Other: Standard treatment according to the Clinical protocols
Registration Number
NCT04184232
Lead Sponsor
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Brief Summary

Treatment of recurrent bladder cancer with dendritic cells

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
17
Inclusion Criteria
  • Histologically confirmed diagnosis of pTa bladder cancer;
  • Patient who require repetitive transurethral resection;
  • Expression of muc-1/wt-1 by the tumor;
  • EGOC 0-3;
Exclusion Criteria
  • any medical condition which can be associated with the high risk for the patient;
  • pregnancy/lactation;
  • chronic infections, including hepatitis B/C, tuberculosis, HIV

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dendritic cellsDendritic cellsPatients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
ControlStandard treatment according to the Clinical protocolsPatients with the recurrent bladder cancer receiving standard treatment
Dendritic cellsStandard treatment according to the Clinical protocolsPatients with the recurrent bladder cancer receiving standard treatment and autologous dendritic cells
Primary Outcome Measures
NameTimeMethod
Efficacy evaluation1 year

1 year relapse free survival

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

🇧🇾

Minsk, Belarus

© Copyright 2025. All Rights Reserved by MedPath